Tianhong (Tina) Li, MD, PhD, from the UC Davis Comprehensive Cancer Center, discusses results from the LUX-Lung 3 trial that examined afatinib as a first-line treatment for patients with EGFR-positive advanced lung adenocarcinoma.
Tianhong Li, MD, PhD
Advertisement
Articles by Tianhong Li, MD, PhD
Dr. Tianhong Li from University of California Davis Cancer Center Describes the Future of Lung Cancer Therapy
Dr. Tianhong Li from UC Davis Cancer Center Discusses the EML4-ALK Fusion Gene
Dr. Tianhong Li from UC Davis Cancer Center Discusses the PROFILE Crizotinib Clinical Trials
Dr. Tianhong (Tina) Li from UC Davic Cancer Center Discusses ALK Gene Mutation Tests
Advertisement
Latest Updated Articles
Dr. Li Discusses the PROFILE Crizotinib Clinical TrialsSeptember 1st 2011
Dr. Li Discusses the EML4-ALK Fusion GeneSeptember 9th 2011
Dr. Li Describes the Future of Lung Cancer TherapySeptember 19th 2011
Dr. Li Reviews Afatinib Data From the LUX-Lung 3 TrialJanuary 17th 2013
Dr. Li Discusses ALK Gene Mutation TestsAugust 29th 2011
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5